Tony Berberabe, MPH | Authors


Enfortumab Vedotin Response Rates, Duration, and Safety Impress in Cisplatin-Ineligible Patients With Urothelial Cancer

February 13, 2021

Response rates to enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors were the highest numerically observed for any regimen, according to findings from study EV-201 presented at the 2021 American Society of Clinical Oncology Genitourinary Cancer Symposium.